These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 6168265)

  • 1. [3H]dihydroergocryptine binding to bovine striatal membranes defined by a low d-butaclamol concentration: antagonism by substituted benzamides.
    Lin CW; Maayani S; Wilk S
    Biochem Pharmacol; 1981 Jun; 30(11):1305-14. PubMed ID: 6168265
    [No Abstract]   [Full Text] [Related]  

  • 2. Dopaminergic activity of four analogs of butaclamol.
    Collu R; Bouvier C; Basak A; Dugas H
    Pharmacol Res Commun; 1985 Dec; 17(12):1153-7. PubMed ID: 2419927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the effect of substituted benzamides in radioreceptor binding assays with their effects on brain dopaminergic systems in vivo.
    Lin CW; Wilk S
    Adv Biochem Psychopharmacol; 1982; 35():51-60. PubMed ID: 6183929
    [No Abstract]   [Full Text] [Related]  

  • 4. Multiple receptors for brain dopamine.
    Titeler M; Weinreich P; Sinclair D; Seeman P
    Proc Natl Acad Sci U S A; 1978 Mar; 75(3):1153-6. PubMed ID: 418405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in guanine nucleotide sensitive and insensitive 3H-ADTN binding in striatum following substantia nigra lesions.
    Hirschhorn ID; Makman MH; Gardner EL
    Eur J Pharmacol; 1980 Mar; 62(1):123-4. PubMed ID: 6154585
    [No Abstract]   [Full Text] [Related]  

  • 6. New detection of brain dopamine receptors with (3H)dihydroergocryptine.
    Tittler M; Weinreich P; Seeman P
    Proc Natl Acad Sci U S A; 1977 Sep; 74(9):3750-3. PubMed ID: 410026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pKa of butaclamol and the mode of butaclamol binding to central dopamine receptors.
    Chrzanowski FA; McGrogan BA; Maryanoff BE
    J Med Chem; 1985 Mar; 28(3):399-400. PubMed ID: 2579238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of the butaclamol template in a search for antipsychotic agents with lessened side effects.
    Kukla MJ; Bloss JL; Brougham LR
    J Med Chem; 1979 Apr; 22(4):401-6. PubMed ID: 34721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping the dopamine receptor. 1. Features derived from modifications in ring E of the neuroleptic butaclamol.
    Humber LG; Bruderlein FT; Philipp AH; Götz M
    J Med Chem; 1979 Jul; 22(7):761-7. PubMed ID: 571916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroleptic receptors: stereoselectivity for neuroleptic enantiomers.
    Seeman P; Westman K; Protiva M; Jílek J; Jain PC; Saxena AK; Anand N; Humber L; Philipp A
    Eur J Pharmacol; 1979 Jun; 56(3):247-51. PubMed ID: 38971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of structural analogs of butaclamol (a new antipsychotic drug) on striatal homovanillic acid and adenyl cyclase of olfactory tubercle in rats.
    Pugsley TA; Merker J; Lippman W
    Can J Physiol Pharmacol; 1976 Aug; 54(4):510-5. PubMed ID: 10057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-dependent interaction of benzamides with dopamine receptors.
    Stefanini E; Marchisio AM; Devoto P; Vernaleone F; Collu R; Spano PF
    Brain Res; 1980 Sep; 198(1):229-33. PubMed ID: 7407589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [3H] 2-Amino-6,7-dihydroxy 1,2,3,4-tetrahydronapthalene (ADTN): a potential specific dopamine receptor ligand.
    Clement-Cormier Y; Abel M
    Res Commun Chem Pathol Pharmacol; 1978 Oct; 22(1):15-25. PubMed ID: 725314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localization of dopamine receptors in rat brain.
    Reisine TD; Nagy JI; Fibiger HC; Yamamura HI
    Brain Res; 1979 Jun; 169(1):209-14. PubMed ID: 455093
    [No Abstract]   [Full Text] [Related]  

  • 15. A comparison of in vitro and in vivo dopamine receptor antagonism produced by substituted benzamide drugs.
    Jenner P; Elliott PN; Clow A; Reavill C; Marsden CD
    J Pharm Pharmacol; 1978 Jan; 30(1):46-8. PubMed ID: 22724
    [No Abstract]   [Full Text] [Related]  

  • 16. Differentiation of solubilized dopamine receptors from spirodecanone binding sites in rat striatum.
    Gorissen H; Ilien B; Aerts G; Laduron P
    FEBS Lett; 1980 Nov; 121(1):133-8. PubMed ID: 6161839
    [No Abstract]   [Full Text] [Related]  

  • 17. [Comparative study of the relative hydrophobicity and interaction with striatal dopamine receptors in the bull of representative dialkylaminoalkyl and dialkylaminoacyl phenothiazine derivatives].
    Brusova EG; Savel'eva MV
    Biull Eksp Biol Med; 1988 Aug; 106(8):163-5. PubMed ID: 2901277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of chlorine substituents on the benzene rings of an analogue of the antipsychotic drug butaclamol on the interaction with dopamine and muscarinic receptors in rat brain.
    Pugsley TA; Lippmann W
    J Pharm Pharmacol; 1979 Jan; 31(1):47-9. PubMed ID: 32368
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of timiperone on 3H-spiroperidol binding to rat striatal dopamine receptors.
    Tachizawa H; Sudo K; Sano M
    Eur J Pharmacol; 1979 Nov; 59(3-4):245-51. PubMed ID: 43256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Participation of an endogenous Ca++-blinding protein activator in the development of drug-induced supersensitivity of striatal dopamine receptors.
    Gnegy M; Uzunov P; Costa E
    J Pharmacol Exp Ther; 1977 Sep; 202(3):558-64. PubMed ID: 19618
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.